TEAM - ANDREA ZUHL

Andrea Zuhl joined Hyku Biosciences in May of 2022. She is a skilled chemical biologist with over a decade of drug discovery experience using chemoproteomics to drive small molecule inhibitor development. Prior to joining the company, she was Chemoproteomics Team Lead in Discovery and Translational Proteomics at Bristol Myers Squibb. Previously, she was a Senior Scientist at AstraZeneca, responsible for small molecule target identification. She received her PhD in Chemistry and Chemical Biology from The Scripps Research Institute and completed a Postdoctoral Fellowship at Pfizer.